Introduction
============

With the booming development of nanotechnology, quantum dots (QDs), nanometer-scale crystalline semiconductors widely used in electronics, have provided great opportunities in the field of neuroscience, due to their excellent optical properties and small size. Functionalized QDs could be a remarkable imaging toolbox for diagnosis of disorders in the nervous system. Feng et al used a QD probe conjugated with an anti-amyloid-β antibody to track the in vivo state of amyloid-β accumulation in mice, suggesting a potential use of QDs for early molecular diagnostic imaging of Alzheimer's disease.[@b1-ijn-11-2737] Apart from reducing undesirable effects of medication and improving therapeutic efficacy, the nanoscale drug delivery of QDs is capable of visualizing and monitoring the process of drug delivery inside a living body.

However, although QDs could facilitate the diagnosis and therapy of some neurological disorders, even cure some presently incurable diseases, they will not be allowed to be used in human beings unless their toxicological profile is clear and methods to control their toxicity are mature. So far, there have been an increasing number of neurotoxicological studies showing that QDs could induce some generally toxic effects, such as damaging the construction and function of neurons and oxidative stress injury, and in particular neurotoxicity, such as behavior changes, neural electrophysiological damage, and learning and memory impairment.[@b2-ijn-11-2737]--[@b6-ijn-11-2737] However, the potential molecular mechanisms of QDs causing these neurotoxic effects at the whole-animal level are underrepresented, which is the important information we hope this study will provide.

The methods used to study the toxic effects of QDs have been mostly based on traditional assays, which are highly reliable and reproducible, but provide less information on specific biological processes and well-defined molecular pathways. Transcriptome sequencing, also known as RNA-seq, is of growing importance in understanding how altered expression of genetic variants contributes to complex diseases. RNA-seq is suitable for gaining mechanistic insights of changes induced by various chemicals, often revealing impacts on biological pathways and processes that had not previously been considered. Even though the use of RNA-seq is becoming more and more popular in toxicology, to date the technology has found only a very marginal application to the study of the effects of QDs in biological systems. Given the substantial lack of knowledge concerning the interaction of novel nanoparticle QDs with the central nervous system (CNS), we chose to rely on new technology, applying an advanced whole-transcriptome analysis to investigate the modulation of gene expression upon treatment of the rat hippocampus with two sizes of CdTe QDs modified with 3-mercaptopropionic acid (MPA), which is one of the most commonly used QDs. Our study group has been studying the toxicity of MPA-modified CdTe QDs for several years, and found these QDs at certain concentrations were able to cause adverse effects on somatic cells, neurons, and model animals, but the potential mechanisms were not clear.[@b7-ijn-11-2737]--[@b10-ijn-11-2737]

In our study, we used intrahippocampal injection of MPA-modified CdTe QDs to stimulate a successfully clinical application of QDs for diagnosis and therapy of neurological disorders in the hippocampus. As the tested MPA-modified CdTe QDs were not conjugated with any biomolecules, our findings of MPA-modified CdTe QDs' toxic effects and potential mechanisms in the CNS, especially the hippocampus, would be clear and explicit. During the study, we observed some adverse effects on MPA-modified CdTe-treated rats behavior, hippocampus, and ultrastructure of neurons and synapses, which could be explained by the findings obtained from RNA-seq, revealing the existence of a rich biodiversity of MPA-modified CdTe QDs with two different sizes. We further found that the downregulated protein expression of phosphorylated Akt (p-Akt), p-ERK1/2, and c-Fos induced by MPA-modified CdTe QDs in rat hippocampus was associated with impaired spatial learning and memory.

Materials and methods
=====================

Quantum dot preparation
-----------------------

The water-soluble MPA-modified CdTe QDs used in this study were prepared as described previously.[@b7-ijn-11-2737],[@b11-ijn-11-2737] Before the study, we evaluated the physicochemical properties of these QDs. High-resolution transmission electron microscopy (TEM) revealed that the average sizes of the MPA-modified CdTe QDs were 2.2±0.25 nm and 3.5±0.49 nm (Figure S1). Dynamic light scattering confirmed that comparable dimensions were 7.39±0.74 nm and 9.82±1.14 nm for 2.2 nm and 3.5 nm MPA-modified CdTe QDs in water solution, respectively (Figure S2A and B). The MPA contributed substantially to the size of the QDs in water. The surface charges through ζ-potential measurement were −31.84±3.06 mV and −26.46±4.75 mV for 2.2 nm and 3.5 nm MPA-modified CdTe QDs in water solution, respectively (Figure S2C and D). The absorption peaks occurred at 514 nm and 578 nm, and the photoluminescence-emission peaks were at 547 nm and 622 nm (excitation wavelength 388 nm) for 2.2 nm and 3.5 nm MPA-modified CdTe QDs in water solution, respectively (Figure S3). Three concentrations of MPA-modified CdTe QD suspensions (400 μg/mL, 800 μg/mL, and 1,600 μg/mL) were prepared by diluting the stock solution (2,200 μg/mL) of QDs, which had been sonicated for 20 minutes, with normal saline just prior to exposure. The concentrations for QDs used here were selected based on preliminary experiments and a series of previous studies.[@b7-ijn-11-2737],[@b9-ijn-11-2737],[@b12-ijn-11-2737]

Animals and treatment
---------------------

A total of 49 male Wistar rats aged 6 weeks with an average body weight of 130--150 g were purchased from Shanghai Super B&K Laboratory Animal Corp Ltd (Shanghai, People's Republic of China). Seven rats were in each group. All rats were housed in stainless steel cages in a ventilated animal facility with the temperature maintained at 22°C±2°C and relative humidity of 65%±10% under a 12-hour light/dark cycle and fed with distilled water and sterilized food. All animal procedures were performed in strict accordance with the animal protocols approved by the Institutional Animal Care and Use Committee of Southeast University.

Rats were anesthetized with chloral hydrate (0.4 g/kg intraperitoneally) and positioned in a stereotaxic apparatus at a surgical level with supplemental injections as needed. The skull was exposed, and two holes were drilled in the skull at stereotaxic coordinates according to the atlas of Paxinos and Franklin: anteroposterior −3.8 mm from bregma; mediolateral ±2 mm from midline; and dorsoventral −3.0 mm from the skull.[@b13-ijn-11-2737] An injection cannula (21 gauge) was inserted into the holes, and 5 μL of different doses of MPA-modified CdTe QDs (six treatments) or normal saline (the control) were injected into each side of the CA1 region at a rate of 10 nL/s with an UltraMicroPump (World Precision Instruments, Sarasota, FL, USA) and the needles left in place for an additional 6 minutes to facilitate diffusion of the solution away from the needle tip. After 3 days of recovery, rats were used for the following experiments.

Open-field test
---------------

The open field (Jiliang, Shanghai, People's Republic of China) contained a 40×40 cm floor and 65 cm high walls. The floor was divided by lines into 16 squares of equal size. A rat was placed in one of four corners of the open field for 3 minutes. Recorded data included distance moved, velocity, duration of movement (velocity \>1.75 cm/s), frequency and time spent in the center of the square arena, rearing incidence (the mouse lifts both its forefeet off the floor), and number of feces.

Y-maze test
-----------

The Y-maze (Jiliang, Shanghai, People's Republic of China) comprised three similar arms arranged 120° apart around a central joining region with an electrified grid floor. A signal light was located at the end of each arm. When the test began, one arm with the light on indicated the shock-free area, whereas the other two arms with the light off indicated a 0.7 mV electric current would pass through the floor (ie, shock area). The rats were placed in a random arm of the Y-maze and allowed to explore for 3 minutes. Electric shocks were delivered to the arms clockwise. The correct response was the rat to run to the light zone within 10 seconds after the light shifted from one arm to another arm. During the test, the rats were considered to have learned the task when they had performed nine correct responses of the ten tests. The learning rate was measured by the number of sessions required to achieve this criterion. At 24 hours later, the test was repeated, and the percentage of correct responses was a measure of memory.

Preparation of hippocampi and histopathological examination
-----------------------------------------------------------

After the Y-maze test (9 days after QD-exposure), all rats were killed after being anesthetized using diethyl ether. The brains were quickly removed and placed on ice, and the hippocampi were dissected and frozen in liquid nitrogen for further tests. The histopathological examination was performed using standard laboratory procedures. The brain tissues were dehydrated using an automatic tissue spine-dryer, embedded in paraffin blocks, and sliced to 5 μm thickness. After hematoxylin--eosin staining, the sections were evaluated by a histopathologist unaware of the treatment allocation using light microscopy. Then, fluorescent and corresponding bright-field images of the slices were observed by fluorescent microscopy (FSX100; Olympus, Tokyo, Japan) to assess the localization of QDs.

Observation of ultrastructure of hippocampal neurons and synapses
-----------------------------------------------------------------

The hippocampi were fixed in fresh 0.1 M sodium cacodylate buffer containing 2.5% glutaraldehyde, followed by a 2-hour fixation period at 4°C with 1% osmium tetroxide in 50 mM sodium cacodylate (pH 7.2--7.4). The specimens were dehydrated in a graded series of ethanol (75%, 85%, 95%, and 100%), embedded in Epon 812, and sliced in an ultramicrotome. Ultrathin sections were strained with uranyl acetate and lead citrate, and observed by TEM (Tecnai G2 Spirit BioTwin; FEI, Hillsboro, OR, USA).

Transcriptome-library preparation and sequencing
------------------------------------------------

Total RNA was obtained from rats exposed to 1,600 μg/mL 2.2 nm or 3.5 nm MPA-modified CdTe QDs using Trizol (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol. Then, total genomic DNA was removed from RNA samples using DNase I (New England BioLabs, Ipswich, MA, USA). RNA purity was assessed using the NanoDrop 2000. Each RNA sample had an A260:A280 ratio above 1.9 (data not shown). Concentrations of the RNA were assessed by Qubit 2.0 (Thermo Fisher Scientific). RNA integrity number was determined for each sample using a Bioanalyzer RNA 6000 Pico Kit (Agilent Technologies, Santa Clara, CA, USA). The complementary cDNA libraries were prepared using the TruSeq RNA Sample Prep Kit v2 (Illumina, San Diego, CA, USA) as per the manufacturer's instructions. The final product was assessed for size distribution using a Bioanalyzer DNA High Sensitivity Kit (Agilent Technologies). Each library was loaded into one lane of the Illumina HiSeq 2500 for 2×125 bp pair-end sequencing. Eight libraries were pooled per HiSeq lane, followed by onboard cluster generation on a Rapid Run pair-end flow cell and subsequent 125 cycles' sequencing (v3 sequencing kit) according to the manufacturer's instructions.

Bioinformatic analysis
----------------------

FastQC was used to control the quality of the data. An initial filtering step was performed to exclude poor-quality reads, including discarding reads with adaptors or unknown base more than 10% and low-quality reads (reads with \>50% bases with quality value ≤5). The clean reads were first mapped onto the rat reference genome (Rn6) independently by TopHat 2.0.10. The "-G" option of TopHat, together with the gene-transfer format file of Ensembl gene annotation, was used for read mapping.[@b14-ijn-11-2737]--[@b16-ijn-11-2737] The remaining parameters were set to default values. Then, the mapped reads of each sample were assembled separately using Cufflinks Version 2.2.1.[@b15-ijn-11-2737] To get high-confidence isoforms, only those assembled transcript with fragments per kilobase of transcript per million mapped reads \>0 were retained for further analyses. Finally, the filtered transcriptome was merged to generate a final transcriptome using Cuffmerge.[@b16-ijn-11-2737] [Figure 1](#f1-ijn-11-2737){ref-type="fig"} shows the main flow diagram of bioinformatic analysis.

Based on the TopHat binary alignment/map file, HTSeq 0.6.1 was used to estimate and quantify gene expression with default parameters, yielding raw read count for each of the protein and long noncoding RNA genes.[@b17-ijn-11-2737] Gene expression was measured in reads per kilobase of exons per million reads mapped. Finally, EdgeR was used to normalize the expression levels in both samples to identify the differentially expressed transcripts by pairwise comparisons.[@b18-ijn-11-2737]

The difference was considered significant if the false-discovery rate was ≤0.05. Gene ontology (GO) enrichment analysis provides all GO terms that are significantly enriched in differentially expressed genes (DEGs), relative to a genome background, and filters the DEGs that correspond to specific biological functions. This method first maps all DEGs to GO terms in the database <http://www.geneontology.org>, calculating gene numbers for every term, and then uses the hypergeometric test to find significantly enriched GO terms in the input list of DEGs. The Database for Annotation, Visualization, and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov>) was used to enrich the DEGs.[@b19-ijn-11-2737] The calculated *P*-value goes through Bonferroni correction, taking a corrected *P*-value ≤0.05 as a threshold. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway-enrichment analysis identifies significantly enriched metabolic pathways or signal-transduction pathways in the whole-genome background using the KEGG oncology-based annotation system,[@b20-ijn-11-2737] with a false-discovery rate ≤0.05 as a threshold to identify an enrichment pathway.

Quantitative real-time reverse-transcription polymerase chain-reaction analysis
-------------------------------------------------------------------------------

Equal quantities of total RNA of each MPA-modified CdTe QD-treatment group were used for quantitative real-time reverse-transcription polymerase chain-reaction (qRT-PCR) analysis, which was carried out as described earlier. The qRT-PCR primers were designed by Primer Premier software, based on the National Center for Biotechnology Information ([Table 1](#t1-ijn-11-2737){ref-type="table"}). Relative quantities of messenger RNA (mRNA) were normalized against the mRNA of the reference gene -- *ACTB*. Three replicates were used for each qRT-PCR analysis.

Western blotting analysis
-------------------------

Both total and phosphorylated protein contents were extracted by radioimmunoprecipitation assay with phenylmethylsulfonyl fluoride (100:1; Beyotime Institute of Biotechnology, Shanghai, People's Republic of China). After centrifugation at 12,000 rpm at 4°C for 15 minutes, the supernatants were collected and stored at −80°C until use. The bicinchoninic acid protein assay (KeyGen Biotech, Nanjing, People's Republic of China) was used to measure the protein concentrations of the extracts of each group. An equal amount (50 mg) of protein was separated on a 10% sodium dodecyl sulfate polyacrylamide gel-electrophoresis gel and electrotransferred to polyvinylidene difluoride membranes that were blocked with 5% bovine serum albumin in Tris-buffered saline containing 0.05% Tween 20 and were rocked gently for at least 1 hour at room temperature. Then, the membranes were incubated with first antibodies of anti-c-Fos (1:200 dilution), anti-ERK1/2 (1:1,000 dilution), anti-p-ERK1/2 (1:1,000 dilution) (Abcam, Cambridge, UK), anti-Akt (1:1,000 dilution), anti-p-Akt (1:2,000 dilution), and anti-GAPDH (1:1,000 dilution) (Cell Signaling Technology Inc, Danvers, MA, USA) at appropriate dilution overnight at 4°C. After being washed with Tris-buffered saline containing 0.05% Tween 20 five times, the membranes were incubated with horseradish peroxidase-conjugated goat antirabbit secondary antibody (1:1,000 dilution) (Beyotime Institute of Biotechnology) for 1 hour at room temperature. Protein bands were visualized using the West Pico chemiluminescence reagent (Thermo Fisher Scientific), and the films were scanned and analyzed by ImageJ 1.48 software. Each experiment was conducted at least three times.

Data analysis
-------------

All data are displayed as mean ± standard deviation. Statistical analysis was performed using SPSS 19.0 (IBM Corporation, Armonk, NY, USA). One-way analysis of variance was used to determine the statistical significance between control and exposed groups, followed by Dunnett's *t*-test to determine the significance of differences between the groups. Probability levels of \<0.05 and \<0.01 were considered statistically significant.

Results
=======

MPA-modified CdTe QDs caused mild effects on the learning efficiency and spatial memory of rats
-----------------------------------------------------------------------------------------------

The open-field test is a widely used procedure for examining the exploratory behavioral effects of chemicals. The role of novelty in the expression of behavioral sensitization will provide neurotoxicity information. Apart from a significantly decreased duration of movement in the high-dose 2.2 nm CdTe-exposure group (*P*\<0.05), other parameters in treatment groups were not significantly different from those in the control (*P*\>0.05) ([Table 2](#t2-ijn-11-2737){ref-type="table"}).

We used the light foot shock-avoidance Y-maze, which is a good method to test learning and memory function, especially on associative learning and spatial memory of rats.[@b21-ijn-11-2737],[@b22-ijn-11-2737] Rats prefer to enter the dark zones at the beginning of the test by nature. After several foot shocks, most rats soon learned to escape from the dark to the light zone to avoid electric shocks, and they learned and remembered that the light zone was a safe region. Therefore, the rats would run to the light zone directly when the light was shifted from one arm to the other. After rats were intrahippocampally injected with 1,600 μg/mL 3.5 nm MPA-modified CdTe QDs, the duration of all responses was significantly larger than those in the control (*P*\<0.05), and the correct rate after 24 hours was significantly lower than that in the control (*P*\<0.05), which indicated that learning efficiency and memory ability were poorer. However, no significant differences were detected in learning or memory parameters between the control and treatment groups (*P*\>0.05) ([Table 3](#t3-ijn-11-2737){ref-type="table"}).

Biodistribution of MPA-modified CdTe QDs in the brain
-----------------------------------------------------

As general fluorescence microscopy cannot achieve nanoscale resolution, we did not observe single nanosized QDs in the brain slices. Fluorescence microscopy was merely able to capture the fluorescence from a certain amount of accumulated QDs, resulting in less clear fluorescent images. However, we still observed QDs fluorescence (green for 2.2 nm CdTe QDs, red for 3.5 nm CdTe QDs), due to their long-lasting fluorescence, even after 9 days of QD exposure. Flashing fluorescent points were shown in the hippocampi of rat brains treated with 1,600 μg/mL MPA-modified CdTe QDs ([Figure 2](#f2-ijn-11-2737){ref-type="fig"}), while the fluorescence in the 400 μg/mL and 800 μg/mL CdTe QD-treatment groups was barely visible (data not shown).

MPA-modified CdTe QDs induced histopathological changes in the hippocampus
--------------------------------------------------------------------------

Hematoxylin--eosin staining showed that inflammatory cell infiltration in the hippocampal CA1 region of rats in the \>800 μg/mL 2.2 nm and 3.5 nm MPA-modified CdTe QD-treatment groups was generally severer than that in the control ([Figure 3](#f3-ijn-11-2737){ref-type="fig"}). Moreover, irregular arrangement of neurons and cellular swelling in the hippocampus were shown, and karyopyknosis and dark staining were observed in some neuron nuclei. There were some foamy cells in the hippocampus, which could have been microglia-consuming QDs, necrotic tissue, or lipids. More seriously, a large amount of cell necrosis was observed in some hippocampi. These pathological lesions were not observed in rats treated with 400 μg/mL CdTe QDs of the two sizes ([Figure 3](#f3-ijn-11-2737){ref-type="fig"}).

MPA-modified CdTe QDs changed the ultrastructure of hippocampal neurons and synapses
------------------------------------------------------------------------------------

TEM images in [Figure 4](#f4-ijn-11-2737){ref-type="fig"} show that neurons in the control group were normal, revealing that shapes of cells and nuclei were irregular, nucleus chromatins stacked, organelles in the cytoplasm abundant, and rough endoplasmic reticulum and free ribosome aggregated into piles. Synapses in the control group were normal as well, showing that presynaptic membranes contained multiple cavities and postsynaptic membranes were dark due to high electron density. In the high-dose MPA-modified CdTe QD-treatment groups, pathological changes in several neurons and synapses were relatively common and severe, including ruptured nuclear membrane, dissolved mitochondrial membrane, aggregated endoplasmic reticulum, and swollen postsynaptic membrane ([Figure 4](#f4-ijn-11-2737){ref-type="fig"}). There were some visible black particles observed in lysosomes of some neurons of the QD-treatment groups, perhaps accumulated QDs not belonging to any particle seen in the control group (Figure S4). The rat hippocampal neurons and synapses in the low- and middle-dose QD-treatment groups were not obviously different from those in the control group and showed only occasional neuronal cytoplasms or postsynaptic membranes that were slightly swollen (Figure S5).

RNA-seq of the rat hippocampal transcriptome
--------------------------------------------

There were three complementary DNA-library preparations sequenced from rat hippocampi sampled from the negative control and 1,600 μg/mL 2.2 nm and 3.5 nm MPA-modified CdTe QD-treatment groups. The average number of total reads produced for each library was approximately 50 million ([Table 4](#t4-ijn-11-2737){ref-type="table"}). After filtering, 44.7--51.8 million clean reads were mapped onto a reference rat-genome data set (University of California Santa Cruz Version rn6), and then the number of unambiguous clean reads for each gene was calculated and normalized to the number of transcripts per million clean reads. Finally, there were 28.1--44.2 million unique mapped reads, and the percentages of these mapped reads of the three groups were all over 95% ([Table 4](#t4-ijn-11-2737){ref-type="table"}), fully saturated and large enough for gene-expression analysis.

Differentially expressed genes in MPA-modified CdTe QD-treatment groups
-----------------------------------------------------------------------

Based on the DEGs calculated by EdgeR, there were 1,192 genes in total differently expressed in two treatment groups, and 55 and 1,180 gene expressions were significantly different from the control group in 1,600 μg/mL 2.2 nm and 3.5 nm MPA-modified CdTe QD-treatment groups, respectively ([Figure 5](#f5-ijn-11-2737){ref-type="fig"}). Heat maps were generated to show the expression values of differently expressed transcripts, including protein genes, known long noncoding RNA, and novel long noncoding RNA, for each group by color based on read count, while as normalized expression-value *z* score moved from −1 to 1, the color changed from red to green ([Figure 6](#f6-ijn-11-2737){ref-type="fig"}). The magnitude distribution of those significantly changed genes in the 2.2 nm and 3.5 nm MPA-modified CdTe QD-treatment groups was illustrated by MA plots and volcano diagrams ([Figure 7](#f7-ijn-11-2737){ref-type="fig"}).

GO enrichment analysis and KEGG enrichment analysis of DEGs
-----------------------------------------------------------

All DEGs identified during CdTe QD exposure were annotated for GO enrichment analysis according to the DAVID dataset. There are three ontologies, ie, biological process, molecular function, and cellular component, that include several terms individually in GO. Following 1,600 μg/mL 2.2 nm MPA-modified CdTe QD exposure, the GO terms of biological process "immune response" and "response to virus" ([Figure 8](#f8-ijn-11-2737){ref-type="fig"}) and only the term of cellular component "integrin complex" were enriched. However, following exposure to 3.5 nm MPA-modified CdTe QDs with the same dose, DEGs were assigned to 135 GO terms in all three ontologies, and biological processes appeared to capture most of these terms (Table S1). The GO terms, which are significantly enriched in DEGs, were relevant to distinct biological processes, with the 15 highest percentages of genes shown in [Figure 8](#f8-ijn-11-2737){ref-type="fig"}.

Compared to the control group, four DEGs enriched pathways in the 2.2 nm CdTe QD-treatment group, while 40 DEGs enriched pathways in the 3.5 nm CdTe QD-treatment group ([Table 5](#t5-ijn-11-2737){ref-type="table"} and Table S2). As shown in [Table 5](#t5-ijn-11-2737){ref-type="table"}, all DEGs enriched pathways in the 2.2 nm CdTe QD-treatment group, and in the 3.5 nm CdTe QD-treatment group, the top 15 DEGs enriched pathways are listed, where most signaling pathways were related to the rat immune system, including some classical inflammatory response and apoptosis pathways, such as the cytosolic DNA-sensing pathway, Toll-like receptor-signaling pathway, and cytokine--cytokine receptor interaction. [Figure 9](#f9-ijn-11-2737){ref-type="fig"} shows the pathways involving changes of genes in immune responses after 3.5 nm MPA-modified CdTe QD treatment in rat hippocampi.

qRT-PCR validation of selected genes in the rat hippocampus under control and MPA-modified CdTe QD conditions
-------------------------------------------------------------------------------------------------------------

As some signaling pathways related to learning and memory in the 1,600 μg/mL 3.5 nm CdTe QD-treatment group were altered, 15 relevant genes were validated by qRT-PCR. All 15 transcripts selected for qRT-PCR were identical to those obtained by RNA-seq, where 13 gene expressions were upregulated and two gene expressions were downregulated ([Table 6](#t6-ijn-11-2737){ref-type="table"}). As shown in [Figure 10](#f10-ijn-11-2737){ref-type="fig"}, the RNA-seq data of the degree of changes in these 15 genes were generally correlated with the data from qRT-PCR analysis, which validated the accuracy and reliability of RNA-seq.

Meanwhile, we investigated the effects of 3.5 nm CdTe QD exposure with different doses on the mRNA levels of *GNGT2*, *PIK3R5*, *DUSP2*, and *PTPN7*. The results showed that \>800 μg/mL 3.5 nm CdTe QD exposure upregulated the gene expression of *GNGT2* and *DUSP2* (*P*\<0.01), while only 1,600 μg/mL upregulated the gene expression of *PIK3R5* and *PTPN7* (*P*\<0.01) ([Figure 11](#f11-ijn-11-2737){ref-type="fig"}). There was a dose--effect relationship.

3.5 nm MPA-modified CdTe QD exposure downregulated the protein expression of p-Akt, p-ERK1/2, and c-Fos in the rat hippocampus
------------------------------------------------------------------------------------------------------------------------------

According to the findings from qRT-PCR, we speculated that 3.5 nm MPA-modified CdTe QD treatment might affect the PI3K--Akt signaling pathway and classical MAPK pathways, resulting in damage to synaptic plasticity ([Figure 12](#f12-ijn-11-2737){ref-type="fig"}). Therefore, we used Western blotting to test three key proteins: Akt, ERK1/2, and c-Fos. The results showed that the total proteins of Akt and ERK1/2, based on the reference protein GAPDH, were not influenced by any dose of 3.5 nm CdTe QD when compared to the control group ([Figure 13A and B](#f13-ijn-11-2737){ref-type="fig"}). However, the expressions of p-Akt and p-ERK1/2, based on Akt and ERK1/2, respectively, were downregulated in rat hippocampi exposed to the 3.5 nm CdTe QD at a concentration over 800 μg/mL ([Figure 13A and B](#f13-ijn-11-2737){ref-type="fig"}). Similarly, the same dose of 3.5 nm CdTe QD exposure caused significant decreases in c-Fos levels, based on GAPDH ([Figure 13C](#f13-ijn-11-2737){ref-type="fig"}).

Discussion
==========

A major problem in the treatment of neurodegenerative diseases, such as Alzheimer's, is the lack of noninvasive methods of trafficking drugs to a particular area of the brain. QD drug delivery offers the possibility of overcoming this problem with better drug targeting, therapeutic efficacy, and fluorescent visibility. Even though the benefits of QD application in biomedicine are plentiful, it is still indispensable to ensure the biosafety of QDs on the nervous system before applying them in living beings. Unfortunately, there have been few neurotoxicological studies of QDs, which makes our study, which deeply investigated the neurotoxicity of CdTe QDs on the hippocampus, valuable.

Our previous study showed that the hippocampus was one of the main targets of nanoparticles, and MPA-modified CdTe QD exposure was capable of inducing hippocampal neuron apoptosis and even death through oxidative stress damage and elevated intracellular calcium levels,[@b9-ijn-11-2737] which could support and promote the investigation of adverse effects and action mechanisms of QDs on the hippocampi of living beings. The hippocampus is an important part of the brain, being responsible for learning and memory. Therefore, the decreased learning-efficiency and memory findings of high-dose MPA-modified CdTe QD-treated animals in this study could indicate that MPA-modified CdTe QDs might damage the hippocampus.

Moreover, studies conducted on freely moving rats have shown that many hippocampal neurons have place fields, which means they fire bursts of action potential when a rat passes through a particular point of the environment.[@b23-ijn-11-2737],[@b24-ijn-11-2737] From the open-field test, we found that low-dose MPA-modified CdTe QDs inhibited exploratory, excitatory, and locomotive activities, while high-dose QDs had the opposite effect. These findings confirm the influence of MPA-modified CdTe QDs of a certain concentration on the hippocampus to a certain extent, but the effects are complicated.

After observing the impairments in spatial learning and memory in MPA-modified CdTe QD-treated rats, we tried to find the reasons for the adverse effects by a series of toxicology and molecular biology approaches. First of all, pathological changes in the hippocampus and damaged ultrastructure of hippocampal neurons and synapses could be an explanation. Hippocampi of rats in the control group merely showed mild inflammation, which might have been due to the injection, while the inflammation became severer with cellular swelling and necrosis when the exposed dose of MPA-modified CdTe QDs increased. Furthermore, TEM provided a chance to observe changes to the ultrastructure of hippocampal neurons and synapses induced by MPA-modified CdTe QDs. Unsurprisingly, pathological lesions on neuron nuclei, mitochondria, the endoplasmic reticulum, and synaptic membranes were observed in the hippocampi of rats treated with the MPA-modified CdTe QDs. Additionally, we found that the lysosomes might be long-term accumulation sites of CdTe QDs in neurons, similar to a previous study,[@b4-ijn-11-2737] which could be partially explained by the findings of Walters et al that negative charge on the QD coating resulted in preferential uptake in neurons.[@b25-ijn-11-2737]

The pathological lesion findings could explain the impaired capabilities of learning and memory in MPA-modified CdTe QD-treated rats. However, the definite mechanisms causing this damage is not yet clear. We used advanced RNA-seq technology to investigate the possible genes affected by MPA-modified CdTe QDs, since the analysis of genome-wide differential RNA expression is capable of providing researchers with greater insights into biological pathways and molecular mechanisms that regulate cell fate, development, and toxicity progression.

We found that most DEGs in the MPA-modified CdTe QD-treatments were categorized into the biological process in the GO enrichment analysis. The top 15 GO terms of biological process in the 3.5 nm CdTe QD-treatment group were related to immunity disorders, such as "immune response", "defense response", "regulation of immune system", and "inflammatory response", and cell damage, such as "regulation of programmed cell death", "regulation of cell death", and "regulation of apoptosis", which was able to explain those pathological lesions. Though there were numerous DEGs in the high-dose MPA-modified CdTe QD-treatment groups, unfortunately no transcripts were found with known roles in neurological signaling or processing with altered expression. It is possible that the high number of transcripts of unknown function in this category contributed to not seeing expected results.[@b26-ijn-11-2737] However, in the KEGG enrichment analysis, we found several pathways regulated by 3.5 nm MPA-modified CdTe QD exposure, related to synaptic plasticity or long-term potentiation (LTP), the foundation of learning, recognition, and memory ([Figure 12](#f12-ijn-11-2737){ref-type="fig"}).

After a comprehensive analysis of [Figure 12](#f12-ijn-11-2737){ref-type="fig"} and [Table 5](#t5-ijn-11-2737){ref-type="table"}, two main components of the Toll-like receptor-signaling pathway, ie, the PI3K--Akt signaling pathway and the classical MAPK pathway (also known as the MAPK--ERK pathway) caught our attention. These are two classically intracellular signaling pathways important in regulating the cell cycle, including cell growth, proliferation, survival, and metabolism. Recently, the two pathways have been found to be necessary components in neural processing.[@b27-ijn-11-2737]--[@b29-ijn-11-2737] As we know, the apoptosis caused by QDs through inhibition of the survival-related signal-transduction proteins of Akt and ERK1/2 has been reported;[@b30-ijn-11-2737],[@b31-ijn-11-2737] however, investigations of their roles in QD-induced adverse effects on the CNS are rare.

Sui et al found that phosphorylation of Akt at the Ser473 residues was activated in response to LTP-inducing high-frequency stimulation in the medial prefrontal cortex, which was able to be suppressed by PI3K inhibitors, resulting in disturbed long-term memory.[@b28-ijn-11-2737] It seems that PI3K and its downstream target, Akt, may play important roles in synaptic plasticity, LTP, and memory formation in the hippocampus. Some studies have suggested that toxins, such as propofol and arsenic, could impair basal synaptic transmission, hippocampal LTP, and memory, along with decreased p-Akt levels.[@b32-ijn-11-2737],[@b33-ijn-11-2737] Our results showed that p-Akt was significantly downregulated in 3.5 nm MPA-modified CdTe QD exposure, which indicated that dysfunction of the PI3K--Akt signaling pathway might be one of the mechanisms of CNS impairment induced by MPA-modified CdTe QD exposure. However, the effects of 3.5 nm MPA-modified CdTe QDs on the phosphorylation of Akt are complicated in view of the findings that the mRNA level of the gene *PIK3R5* (encoding PI3K) was significantly upregulated in high-dose 3.5 nm MPA-modified CdTe QD exposure, and decreased p-Akt levels were not dose-dependent.

Thus far, it has been reported that the ERK-signaling pathway has an important link with the higher functions of learning and memory.[@b27-ijn-11-2737],[@b34-ijn-11-2737] Decreased phosphorylation of ERK1/2 has been observed in hippocampi exposed to ketamine and chronic multiple stress with impaired learning and memory,[@b35-ijn-11-2737],[@b36-ijn-11-2737] while upregulation of the MAPK--ERK signaling pathway via drugs can enhance the cognitive performance of mice.[@b37-ijn-11-2737] Therefore, the decreased level of p-ERK1/2 and increased expression of *DUSP2* and *PTPN7* (encoding MKP and PTP, activity of which inhibits ERK activity)[@b38-ijn-11-2737],[@b39-ijn-11-2737] observed in 3.5 nm MPA-modified CdTe QD treatment suggested the inhibition of ERK pathway might be another of the mechanisms of CdTe QD causing impairment in spatial learning and memory in rats.

As the activation of ERK in mature neurons results in a translocation from the cytoplasm into the nucleus, the regulation of certain nuclear transcription factors may be one of the roles of the ERK-signaling system in the process of LTP and synaptic plasticity.[@b40-ijn-11-2737],[@b41-ijn-11-2737] The transcription factor c-Fos, encoded by immediate early gene *CFOS*, is an important downstream ERK1/2-signaling component for the formation of long-term modification of synaptic response. It has been confirmed that p-ERK1/2 can mediate the upregulation of c-Fos expression, which enables neurons to transcribe and translate the corresponding proteins affecting memory function.[@b42-ijn-11-2737],[@b43-ijn-11-2737] When mice were lacking c-Fos in the CNS, they were specifically impaired in hippocampus-dependent spatial and associative learning tasks.[@b44-ijn-11-2737] Additionally, downregulated c-Fos expression following toxin exposure has been implicated in neuronal damage.[@b45-ijn-11-2737]--[@b47-ijn-11-2737] Here, we observed c-Fos levels were significantly decreased in the 3.5 nm CdTe QD-treated group in a dose-dependent pattern, which suggested that downregulation of c-Fos was involved in the process of MPA-modified CdTe QD-induced neurotoxic effects.

As we know, there are multiple factors, such as concentration, size, and outer coating, on which the toxicity of QDs depends, apart from the inherent toxicity of core materials.[@b8-ijn-11-2737],[@b48-ijn-11-2737],[@b49-ijn-11-2737] Given that the dose-- and size--effect relationship of MPA-modified CdTe QDs has been investigated here, the role of functionalized ligand MPA should be investigated in further studies, as well as other key molecular targets.

Conclusion
==========

In this study, the neurotoxicity of MPA-modified CdTe QDs was evaluated. The results showed that MPA-modified CdTe QDs of less than a certain concentration had no significant toxicity on the hippocampus, which suggested MPA-modified CdTe QDs are promising for further use in biomedicine. However, we still observed some pathological lesions in the rat hippocampus and impairments in spatial recognition and memory induced by MPA-modified CdTe QDs at high doses and/or of certain size, which promoted us to investigate the specific mechanisms of MPA-modified CdTe QDs causing these adverse effects. Our present findings of the inhibited phosphorylation of Akt and ERK1/2 and decreased level of the subsequent transcription of c-Fos elucidated an important molecular mechanism underlying the impairments in spatial recognition and memory caused by MPA-modified CdTe QDs. Otherwise, owning to the largely complex mechanisms of MPA-modified CdTe QDs, we will conduct further research according to the ample molecular targets of MPA-modified CdTe QDs provided by RNA-seq.
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![Main flow diagram of transcriptome sequencing.\
**Abbreviations:** QC, quality control; KEGG, Kyoto Encyclopedia of Genes and Genomes; lncRNA, long noncoding RNA; GO, gene ontology.](ijn-11-2737Fig1){#f1-ijn-11-2737}

![Fluorescent and corresponding bright-field images of 2.2 nm and 3.5 nm MPA-capped CdTe QD-exposed hippocampus CA1 region of rats.\
**Notes:** Green for 2.2 nm CdTe QDs, red for 3.5 nm CdTe QDs. Scale bar 64 μm.\
**Abbreviations:** MPA, 3-mercaptopropionic acid; QD, quantum dot.](ijn-11-2737Fig2){#f2-ijn-11-2737}

![Histological analysis of hippocampus of rats treated with 2.2 nm and 3.5 nm MPA-capped CdTe QDs.\
**Notes:** Black arrows indicate foamy cells, red arrows indicate neutrophils, blue arrows indicate accumulated QDs, green arrow indicate necrotic cells, yellow arrows indicate swollen blood vessels.\
**Abbreviations:** MPA, 3-mercaptopropionic acid; QDs, quantum dots.](ijn-11-2737Fig3){#f3-ijn-11-2737}

![Transmission electron microscopy images of hippocampus of rats treated with 2.2 nm and 3.5 nm MPA-capped CdTe QDs. The arrows indicate accumulated QDs in the lysosome.\
**Note:** The insets are magnifications of parts of neurons.\
**Abbreviations:** MPA, 3-mercaptopropionic acid; QDs, quantum dots; M, mitochondria; N, nucleus; L, lysosome; NC, nucleolus; PreM, presynaptic membrane; postM, postsynaptic membrane; RER, rough endoplasmic reticulum.](ijn-11-2737Fig4){#f4-ijn-11-2737}

![Venn diagram showing number of genes identified, with different expressions on each of the samples.\
**Abbreviation:** lncRNA, long noncoding RNA.](ijn-11-2737Fig5){#f5-ijn-11-2737}

![Heat map representing expression patterns of significantly expressed genes, with green indicating downregulation and red indicating upregulation.\
**Notes:** (**A**) Protein genes; (**B**) known lncRNA; and (**C**) novel lncRNA.\
**Abbreviation:** lncRNA, long noncoding RNA.](ijn-11-2737Fig6){#f6-ijn-11-2737}

![MA plots and volcano diagrams representing differently expressed genes.\
**Notes:** MPA-capped CdTe QD (2.2 nm) treatment (**A**) and MPA-capped CdTe QD (3.5 nm) treatment (**B**), with the control (red dots indicating significantly expressed genes and black dots indicating insignificantly expressed genes).\
**Abbreviations:** MPA, 3-mercaptopropionic acid; QDs, quantum dot; FC, fold change; FDR, false-discovery rate.](ijn-11-2737Fig7){#f7-ijn-11-2737}

![All GO terms and top 15 GO terms of genes differentially expressed.\
**Notes:** MPA-capped CdTe QD (2.2 nm and 3.5 nm) exposure on rat hippocampus based on the biological processes associated with GO. Differences between the 2.2 nm CdTe QD treatment and the control are indicated by gray bars, while differences between the 3.5 nm CdTe QD treatment and the control are indicated by black bars. Percentages are based on the proportion of the number of genes in each term.\
**Abbreviations:** GO, gene ontology; MPA, 3-mercaptopropionic acid; QD, quantum dot.](ijn-11-2737Fig8){#f8-ijn-11-2737}

![Changes in genes in immune-response pathways after CdTe QD treatment in rat hippocampus.\
**Notes:** Gene products are shown in black font, and gene names are colored and italicized. Colors of gene names indicate the direction of differential expression observed between 3.5 nm MPA-capped CdTe QD treatment and control (red, up; green, down). No gene name indicates no significant change. Connected edges between gene products described their interactions (solid edge, direct interaction; dashed edge, indirect interaction).\
**Abbreviations:** MPA, 3-mercaptopropionic acid; QD, quantum dot; DC, dendritic cell; ROS, reactive oxygen species; ER, endoplasmic reticulum; SR, sarcoplasmic reticulum.](ijn-11-2737Fig9){#f9-ijn-11-2737}

![Relationship between relative change of gene expression measured by qRT-PCR and transcriptome sequencing. *R* is the Pearson's correlation coefficient.\
**Abbreviation:** qRT-PCR, quantitative real-time reverse-transcription polymerase chain reaction.](ijn-11-2737Fig10){#f10-ijn-11-2737}

![Effects of 3.5 nm MPA-capped CdTe QD exposure on the gene expression of *GNGT2*, *DUSP2*, *PIK3R5*, and *PTPN7* in rat hippocampus.\
**Notes:** ^\*^*P*\<0.05; ^\*\*^*P*\<0.01. Data shown are mean ± SD (n=3). One-way analysis of variance followed by Dunnett's post hoc test used for statistical analysis at each testing time point.\
**Abbreviations:** MPA, 3-mercaptopropionic acid; QD, quantum dot; SD, standard deviation; mRNA, messenger RNA.](ijn-11-2737Fig11){#f11-ijn-11-2737}

![Changes of relevant genes in learning and memory pathways after CdTe QD treatment in rat hippocampus.\
**Notes:** Gene products are shown in black font, and gene names are colored and italicized. Colors of gene names indicate the direction of differential gene expression observed between 3.5 nm MPA-capped CdTe QD treatment and control in qRT-PCR analysis (red, up; green, down). No gene name indicates no significant change. Colors of gene-product boxes indicate the direction of differential protein expression observed between 3.5 nm MPA-capped CdTe QD treatment and control in Western blotting analysis (red, up; green, down). Connected edges between gene products described their interactions (solid edge, direct interaction; dashed edge, indirect interaction).\
**Abbreviations:** MPA, 3-mercaptopropionic acid; QD, quantum dot; qRT-PCR, quantitative real-time reverse-transcription polymerase chain reaction; ER, endoplasmic reticulum; SR, sarcoplasmic reticulum.](ijn-11-2737Fig12){#f12-ijn-11-2737}

![Effects of 3.5 nm MPA-capped CdTe QD exposure on the protein expression of Akt, ERK1/2, their corresponding phosphorylated (p-) proteins, and c-FOS on rat hippocampus.\
**Notes:** (**A**) Representative Western blot of Akt, p-Akt, and GAPDH (reference protein). The density of each band was measured, and the ratios of Akt:GAPDH and p-Akt:Akt were calculated. (**B**) Representative Western blot of ERK1/2, p-ERK1/2, and GAPDH. The density of each band was measured, and the ratios of ERK1/2:GAPDH and p-ERK1/2:ERK1/2 were calculated. (**C**) Representative Western blot of c-Fos and GAPDH. The density of each band was measured, and the ratio of c-Fos:GAPDH was calculated. Data shown are mean ± SD (n=3). One-way analysis of variance followed by Dunnett's post hoc test used for statistical analysis at each testing time point. ^\*^*P*\<0.05; ^\*\*^*P*\<0.01.\
**Abbreviations:** MPA, 3-mercaptopropionic acid; QD, quantum dot.](ijn-11-2737Fig13){#f13-ijn-11-2737}

###### 

Designed qRT-PCR primers of genes used to validate the results of RNA-seq

  Gene ID              Gene symbol   Designed qRT-PCR primers   
  -------------------- ------------- -------------------------- ----------------------
  ENSRNOG00000006108   *GNGT2*       TGGAGCAGTTGAAGAAGGAA       GGGATTCTTGTCTTCTGGGA
  ENSRNOG00000017606   *P2RX1*       TTAAGCTCCCAGTCAGCCTT       ACACAAATGCTGTGGGTGTT
  ENSRNOG00000014776   *ADCY7*       TATGCAGACATCGTGGGTTT       CCACTAGCTCCTTGGGAGAG
  ENSRNOG00000016346   *PRKCD*       TCCAAGGACATCATGGAGAA       TCCTGTTACTCCCAGCCTCT
  ENSRNOG00000005809   *ARHGDIB*     GGCCTGAAGTATGTTCAGCA       CTTGGGAGCCTCCTCTACTG
  ENSRNOG00000020401   *ADCY4*       TTCACAATCCAAATGCTGGT       TGAGAAGCAGACGAAGAGGA
  ENSRNOG00000013862   *DUSP2*       CCAACCACTTTGAGGGTCTT       AGTCAATGAAGCCGATAGCC
  ENSRNOG00000019311   *NFKB2*       GGCAGACTGGTGTCATTGAG       CCAGTGATTACTGCCAGGTG
  ENSRNOG00000005378   *GNA15*       CATCTACCTGGCGTCTCTGA       CGTGCTAAACAGAGCGAGAC
  ENSRNOG00000023428   *PIK3R5*      TTCCACTGTCCTCTGCACTC       AGGAAGCAGTGGTAGGTGCT
  ENSRNOG00000005807   *PTPN7*       CACTGGCTTGTCTTTGTGCT       GGAATGGCTTTCAGGAACAT
  ENSRNOG00000020657   *SHC1*        CCTGGGAAGGAGTAACCTGA       CCAGACGCGAATGAGATAGA
  ENSRNOG00000013231   *PTAFR*       CTAGGATGGGTGCATGTTTG       GCAGTGTTCTGAGGTAGCCA
  ENSRNOG00000004890   *ADCY8*       TACGACCTTGTCTGCTCAGG       ATGCGAAGACAGTGATGCTC
  ENSRNOG00000005048   *TRHR*        TGCTGTGGTTCTTCCTTCTG       GACGCCAAAGTCCATTAGGT
                       *ACTB*        CGGTCAGGTCATCACTATCG       TTCCATACCCAGGAAGGAAG

**Abbreviation:** qRT-PCR, quantitative real-time reverse-transcription polymerase chain reaction.

###### 

Effects of MPA-capped CdTe QDs on exploratory behavior of rats

  Group         Dose (μg/mL)      Parameters                                                                                                                                                                
  ------------- ----------------- ----------------- ----------- --------------------------------------------------------- -------------------------------------------------------- ------------ ----------- -----------
  Control       0                 3,482.38±142.34   2.9±1.61    3.4±1.67                                                  162.42±2.02                                              19.41±0.76   15.6±1.14   3±1.87
  2.2 nm CdTe   400               3,268.98±409.11   3.87±2.37   2.2±2.17                                                  158.85±2.8[\*](#tfn2-ijn-11-2737){ref-type="table-fn"}   19.26±1.26   14±1.22     2.4±2.3
  800           3,409.66±524.59   5.17±5.05         3.6±0.55    164.24±1.72                                               18.96±2.9                                                15.4±2.51    2.8±2.28    
  1,600         3,518.14±352.97   2.97±1.61         3.2±1.14    166.36±1.75[\*](#tfn2-ijn-11-2737){ref-type="table-fn"}   19.59±2.01                                               16±2.91      1.6±1.52    
  3.5 nm CdTe   400               3,182.4±321.29    2.54±2.96   2.5±1.91                                                  162.03±4.95                                              17.7±1.77    16.5±3.11   2.75±2.06
  800           3,818.4±278.86    2.89±2.57         2.75±0.96   162.57±1.34                                               21.36±1.59                                               15±2.34      1.4±1.34    
  1,600         3,487.57±180.74   4.44±0.91         3.6±1.82    163.11±1.09                                               19.46±1.05                                               16.2±1.64    0.6±0.89    

**Notes:**

*P*\<0.05. Data presented as mean ± SD (n=5). One-way analysis of variance followed by Dunnett's post hoc test used for statistical analysis.

**Abbreviations:** MPA, 3-mercaptopropionic acid; QDs, quantum dots; SD, standard deviation.

###### 

Effects of MPA-capped CdTe QDs' nerve injury on learning and memory parameters of rats in the Y-maze

  Group         Dose (μg/mL)                                            Parameters                                                                                                                                  
  ------------- ------------------------------------------------------- ------------------------------------------------------------ ------------- ---------- ----------------------------------------------------- ---------
  Control       0                                                       19±1.58                                                      963.4±57.57   7.2±2.86   4±3                                                   72±1.3
  2.2 nm CdTe   400                                                     18.6±1.34                                                    957±67.61     6±1.41     5±2.55                                                74±1.14
  800           20±2.91                                                 993.6±72.68                                                  9.2±6.14      5±5.24     70±1.22                                               
  1,600         22.6±2.07[\*](#tfn4-ijn-11-2737){ref-type="table-fn"}   1,073.6±137.14                                               10±4.18       2.8±1.79   70±1.84                                               
  3.5 nm CdTe   400                                                     19±1.87                                                      976.6±77.22   6±4.3      6.4±2.97                                              70±1.58
  800           19.4±2.3                                                959.4±114.97                                                 6.4±2.88      7±4.41     72±1.44                                               
  1,600         21.2±1.92                                               1,135.4±106.93[\*](#tfn4-ijn-11-2737){ref-type="table-fn"}   6±3.39        6.6±4.61   67±1.75[\*](#tfn4-ijn-11-2737){ref-type="table-fn"}   

**Notes:**

*P*\<0.05. Data presented as mean ± SD (n=5). One-way analysis of variance followed by Dunnett's post hoc test used for statistical analysis.

**Abbreviations:** MPA, 3-mercaptopropionic acid; QDs, quantum dots; SD, standard deviation.

###### 

Summary of RNA-seq data collected from hippocampal tissues of Wistar rats treated with MPA-capped CdTe QDs

  Term                  Control      2.2 nm QDs   3.5 nm QDs
  --------------------- ------------ ------------ ------------
  Total reads           49,732,220   52,093,756   44,994,962
  Clean reads           49,325,636   51,843,210   44,742,342
  Total mapped reads    44,478,598   46,374,435   40,186,899
  Total mapped rate     90.2%        89.5%        89.8%
  Unique mapped reads   42,251,128   44,204,014   38,161,122
  Unique mapped rate    95%          95.3%        95%

**Abbreviations:** MPA, 3-mercaptopropionic acid; QDs, quantum dots.

###### 

Differentially expressed pathways and top ten differentially expressed pathways in the control with 2.2 nm and 3.5 nm MPA-capped CdTe QD treatment

  Term                                        Pathway ID   Input number of gene   Background number of gene   Corrected *P*-value
  ------------------------------------------- ------------ ---------------------- --------------------------- ---------------------
  **2.2 nm CdTe QDs vs control**                                                                              
  Influenza A                                 rno05164     6                      151                         0.00391411
  *Staphylococcus aureus* infection           rno05150     3                      45                          0.018418904
  Herpes simplex infection                    rno05168     5                      176                         0.018418904
  Cytosolic DNA-sensing pathway               rno04623     3                      46                          0.018418904
  **3.5 nm CdTe QDs vs control**                                                                              
  *Staphylococcus aureus* infection           rno05150     23                     45                          3.86^−8^
  Antigen processing and presentation         rno04612     21                     73                          0.000182151
  Chagas disease (American trypanosomiasis)   rno05142     23                     87                          0.000182151
  Toll-like receptor-signaling pathway        rno04620     22                     81                          0.000182151
  Tuberculosis                                rno05152     31                     148                         0.000182151
  Leishmaniasis                               rno05140     19                     64                          0.000182151
  Cytokine--cytokine receptor interaction     rno04060     36                     189                         0.000182151
  Osteoclast differentiation                  rno04380     26                     113                         0.000182151
  Cell-adhesion molecules                     rno04514     29                     136                         0.000182151
  Pertussis                                   rno05133     18                     61                          0.000224868

**Abbreviations:** MPA, 3-mercaptopropionic acid; QD, quantum dot.

###### 

Selected qRT-PCR determinations of fold changes in gene expression in 1,600 μg/mL 3.5 nm MPA-capped CdTe QD treatment, compared with RNA-seq data

  Gene symbol   qRT-PCR   RNA-seq    Description              
  ------------- --------- ---------- ------------- ---------- --------------------------------------------------------------------------------------
  *GNGT2*       12.78     9.61^−8^   46.28         1.68^−8^   Guanine nucleotide-binding protein (G protein), γ-transducing activity polypeptide 2
  *P2RX1*       3.28      6.54^−8^   20.95         5.65^−3^   Purinergic receptor P2X, ligand-gated ion channel 1
  *ADCY7*       4.32      4.33^−7^   9.39          1.17^−5^   Adenylate cyclase 7
  *PRKCD*       4.64      4.44^−8^   6.80          1.47^−5^   Protein kinase Cδ
  *ARHGDIB*     5.86      1.92^−6^   5.81          5.10^−5^   Rho, GDP-dissociation inhibitor (GDI) beta
  *ADCY4*       3.67      2.75^−6^   4.92          1.38^−3^   Adenylate cyclase 4
  *DUSP2*       2.27      1.70^−3^   4.78          8.27^−3^   Dual-specificity phosphatase 2
  *NFKB2*       2.62      3.97^−5^   4.30          6.49^−3^   Nuclear factor of κ-light polypeptide gene enhancer in B cells 2, p49/p100
  *GNA15*       3.03      1.18^−3^   4.27          3.63^−3^   Guanine nucleotide-binding protein, α15
  *PIK3R5*      3.18      9.98^−7^   4.20          4.18^−3^   Phosphoinositide-3-kinase, regulatory subunit 5
  *PTPN7*       3.13      3.33^−3^   3.94          1.27^−2^   Protein tyrosine phosphatase, nonreceptor type 7
  *SHC1*        1.73      3.23^−3^   3.42          1.08^−2^   SHC (Src homology 2 domain-containing) transforming protein 1
  *PTAFR*       2.13      3.78^−5^   3.41          1.22^−2^   Platelet-activating factor receptor
  *ADCY8*       0.37      7.06^−4^   0.32          3.29^−2^   Adenylate cyclase 8 (brain)
  *TRHR*        0.18      1.91^−5^   0.18          1.16^−3^   Thyrotrophin-releasing hormone receptor

**Abbreviations:** qRT-PCR, quantitative real-time reverse-transcription polymerase chain reaction; MPA, 3-mercaptopropionic acid; QD, quantum dot.
